Korsana Biosciences, Inc. SEC filings KRSA

Korsana Biosciences, Inc. has 391 filings in SEC EDGAR's recent list, going back to Oct 9, 2018. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.

Korsana Biosciences, Inc. SEC filings
Form Description Filed Period
DEF 14A Proxy statement Oct 15, 2026 Nov 13, 2026
PRE 14A Preliminary proxy statement Oct 5, 2026 Oct 5, 2026
DEFA14A Additional proxy material Apr 29, 2025 —
DEF 14A Proxy statement Apr 29, 2025 Jun 16, 2025
DEFA14A Additional proxy material Apr 29, 2024 —
DEF 14A Proxy statement Apr 29, 2024 Jun 14, 2024
DEFM14A Filing Jun 20, 2023 —
PREM14A Filing Jun 9, 2023 Jun 9, 2023
DEFA14A Additional proxy material May 12, 2023 —
DEFA14A Additional proxy material Apr 3, 2023 —
DEF 14A Proxy statement Apr 3, 2023 May 15, 2023
PRE 14A Preliminary proxy statement Mar 22, 2023 May 15, 2023
DEFA14A Additional proxy material Apr 26, 2022 —
DEF 14A Proxy statement Apr 26, 2022 Jun 14, 2022
DEFA14A Additional proxy material Apr 28, 2021 —
DEF 14A Proxy statement Apr 28, 2021 Jun 24, 2021
DEFA14A Additional proxy material Apr 23, 2020 —
DEF 14A Proxy statement Apr 23, 2020 Jun 16, 2020

Showing 18 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
KRSA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
MA
Headquarters
Waltham, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1755237
Former names
Cyclerion Therapeutics, Inc. (until Aug 27, 2026)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.